Compound Evidence File
#EC-2026-0381
PNC 27
Filed under Peptides. The bureau holds 121 laboratory returns for this compound from 37 distinct subjects. Scores below are per-subject aggregates; open a subject row for the underlying evidence.
Cross-Index
Subjects Shipping This Compound
37 SUBJECTS| Subject | Grade | Samples | Mean | Min | Max | First seen | Last seen |
|---|---|---|---|---|---|---|---|
| Tianjin Finder Chemical TFCCASE #VI-2026-0693 | A | 7 | 10.0 | 9.9 | 10.0 | 14 Nov 2025 | 16 Apr 2026 |
| HomopeptideCASE #VI-2026-0760 | A | 5 | 10.0 | 9.9 | 10.0 | 24 May 2026 | 24 May 2026 |
| Sangon BioCASE #VI-2026-0671 | A | 4 | 10.0 | 10.0 | 10.0 | 26 Apr 2026 | 4 Jul 2026 |
| JEEP PeptidesCASE #VI-2026-0457 | A | 4 | 10.0 | 9.9 | 10.0 | 16 Jan 2026 | 3 Jul 2026 |
| Shanghai Sigma AudleyCASE #VI-2026-0505 | A | 4 | 10.0 | 9.9 | 10.0 | 5 Jan 2026 | 16 Apr 2026 |
| Sigma-AldrichCASE #VI-2026-0829 | A | 4 | 10.0 | 10.0 | 10.0 | 2 Feb 2026 | 7 Aug 2026 |
| PolyPeptide GroupCASE #VI-2026-0143 | A | 4 | 10.0 | 10.0 | 10.0 | 13 Feb 2026 | 5 Mar 2026 |
| Shanghai ERP BiotechnologyCASE #VI-2026-0936 | A | 3 | 10.0 | 10.0 | 10.0 | 13 Feb 2026 | 3 Jun 2026 |
| BachemCASE #VI-2026-0314 | A | 3 | 10.0 | 9.9 | 10.0 | 16 Jan 2026 | 15 Jun 2026 |
| Flourishglobal PeptideCASE #VI-2026-0630 | A | 3 | 10.0 | 9.9 | 10.0 | 7 Dec 2025 | 12 Jul 2026 |
| Thermo Fisher ScientificCASE #VI-2026-0142 | A | 3 | 10.0 | 9.9 | 10.0 | 9 Apr 2026 | 2 Jun 2026 |
| QYAOBIOCASE #VI-2026-0861 | A | 4 | 9.9 | 9.9 | 10.0 | 2 May 2026 | 26 Jun 2026 |
| Kerui PeptidesCASE #VI-2026-0626 | A | 4 | 9.9 | 9.9 | 10.0 | 18 Mar 2026 | 5 May 2026 |
| SinoPepCASE #VI-2026-0387 | A | 4 | 9.9 | 9.9 | 10.0 | 18 Dec 2025 | 10 Aug 2026 |
| AsymchemCASE #VI-2026-0091 | A | 4 | 9.9 | 9.9 | 10.0 | 12 May 2026 | 12 Jul 2026 |
| Mokemei BiotechnologyCASE #VI-2026-0540 | A | 3 | 9.9 | 9.9 | 9.9 | 23 Jan 2026 | 13 Jul 2026 |
| WuXi TIDESCASE #VI-2026-0335 | A | 3 | 9.9 | 9.9 | 10.0 | 6 Dec 2025 | 11 Jun 2026 |
| Hybio PharmaceuticalCASE #VI-2026-0065 | A | 3 | 9.9 | 9.9 | 9.9 | 15 Apr 2026 | 12 Aug 2026 |
| GenScript PeptidesCASE #VI-2026-0860 | A | 3 | 9.9 | 9.9 | 9.9 | 21 Feb 2026 | 16 Jun 2026 |
| AmbioPharmCASE #VI-2026-0177 | A | 3 | 9.9 | 9.9 | 10.0 | 1 May 2026 | 5 Aug 2026 |
| Hubei JianxiangCASE #VI-2026-0048 | A | 2 | 9.9 | 9.9 | 10.0 | 13 Jan 2026 | 26 Apr 2026 |
| Shanghai Wibson BiotechnologyCASE #VI-2026-0379 | A | 2 | 9.9 | 9.9 | 10.0 | 4 Apr 2026 | 21 Apr 2026 |
| Chinese Peptide CompanyCASE #VI-2026-0184 | A | 2 | 9.9 | 9.9 | 10.0 | 9 Feb 2026 | 12 Jul 2026 |
| Wuhan Wansheng Bio (WWB)CASE #VI-2026-0594 | A | 7 | 9.2 | 8.1 | 10.0 | 25 May 2026 | 25 May 2026 |
| Glbiochem (Shanghai)CASE #VI-2026-0704 | A | 7 | 8.9 | 7.5 | 10.0 | 23 May 2026 | 23 May 2026 |
| Nantong Guangyuan Chemical GYCCASE #VI-2026-0284 | A | 5 | 8.5 | 7.2 | 9.5 | 21 May 2026 | 21 May 2026 |
| Nanjing Xiyuxun Technology XYXCASE #VI-2026-0433 | X | 1 | 8.1 | 8.1 | 8.1 | 28 Mar 2025 | 28 Mar 2025 |
| HazelCASE #VI-2026-0392 | X | 1 | 8.1 | 8.1 | 8.1 | 9 Jun 2025 | 9 Jun 2025 |
| Shanghai Sigma Audley SSACASE #VI-2026-0486 | A | 8 | 7.9 | 6.5 | 10.0 | 21 May 2026 | 21 May 2026 |
| LSPLCASE #VI-2026-0523 | X | 3 | 7.5 | 7.0 | 7.9 | 25 Apr 2025 | 24 May 2026 |
| Shandong Nuoweiou Medical Technology CoCASE #VI-2026-0076 | X | 1 | 7.2 | 7.2 | 7.2 | 8 Jul 2025 | 8 Jul 2025 |
| Changan District Sheng Peptide TradingCASE #VI-2026-0341 | X | 1 | 7.2 | 7.2 | 7.2 | 7 May 2025 | 7 May 2025 |
| Oasis PeptidesCASE #VI-2026-0404 | X | 1 | 7.2 | 7.2 | 7.2 | 7 May 2025 | 7 May 2025 |
| Qingdao Sigma Chemical QSCCASE #VI-2026-0538 | A | 2 | 6.8 | 6.5 | 7.2 | 23 May 2026 | 23 May 2026 |
| Yongkang Nuoao Trading CoCASE #VI-2026-0646 | X | 1 | 5.6 | 5.6 | 5.6 | 3 Jul 2025 | 3 Jul 2025 |
| Biolabshop LimitedCASE #VI-2026-0832 | X | 1 | 2.9 | 2.9 | 2.9 | 24 Apr 2025 | 24 Apr 2025 |
| Peptide ArkCASE #VI-2026-0350 | X | 1 | 0.0 | 0.0 | 0.0 | 17 Dec 2024 | 17 Dec 2024 |
Open any subject to view the batch-level evidence for PNC 27 alone.